
## Dinesh Kumar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2291387/publications.pdf Version: 2024-02-01



DINESH KIIMAD

#	Article	IF	CITATIONS
1	Polymorphs, Salts, and Cocrystals: What's in a Name?. Crystal Growth and Design, 2012, 12, 2147-2152.	3.0	767
2	Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. Advanced Drug Delivery Reviews, 2017, 117, 25-46.	13.7	239
3	Multidrug co-crystals: towards the development of effective therapeutic hybrids. Drug Discovery Today, 2016, 21, 481-490.	6.4	164
4	Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials, 2012, 33, 6758-6768.	11.4	159
5	Co amorphous systems: A product development perspective. International Journal of Pharmaceutics, 2016, 515, 403-415.	5.2	139
6	Micellar carriers for the delivery of multiple therapeutic agents. Colloids and Surfaces B: Biointerfaces, 2015, 135, 291-308.	5.0	78
7	Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: A case study with aceclofenac. International Journal of Pharmaceutics, 2014, 461, 459-468.	5.2	63
8	Evaluation of the inhibitory potential of HPMC, PVP and HPC polymers on nucleation and crystal growth. RSC Advances, 2016, 6, 77569-77576.	3.6	63
9	Modelling and understanding powder flow properties and compactability of selected active pharmaceutical ingredients, excipients and physical mixtures from critical material properties. International Journal of Pharmaceutics, 2017, 531, 191-204.	5.2	33
10	Crystal engineered albendazole with improved dissolution and material attributes. CrystEngComm, 2016, 18, 1489-1494.	2.6	30
11	Ionic, Neutral, and Hybrid Acid–Base Crystalline Adducts of Lamotrigine with Improved Pharmaceutical Performance. Crystal Growth and Design, 2015, 15, 5816-5826.	3.0	29
12	Comparison of wet milling and dry milling routes for ibuprofen pharmaceutical crystals and their impact on pharmaceutical and biopharmaceutical properties. Powder Technology, 2018, 330, 228-238.	4.2	25
13	Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol. International Journal of Pharmaceutics, 2015, 491, 26-34.	5.2	21
14	Effect of HPMC concentration on crystal habit of nifedipine. CrystEngComm, 2015, 17, 1615-1624.	2.6	17
15	Effect of surfactant concentration on nifedipine crystal habit and its related pharmaceutical properties. Journal of Crystal Growth, 2015, 422, 44-51.	1.5	17
16	Designed Isomorphism of Nifedipine: A Joint Experimental and Molecular Simulation Study with Screened Solvents and Antisolvents. Crystal Growth and Design, 2014, 14, 326-338.	3.0	13
17	Impact of Nisoldipine Crystal Morphology on Its Biopharmaceutical Properties: A Layer Docking Assisted Study. Organic Process Research and Development, 2015, 19, 1912-1917.	2.7	10
18	Design of a novel type IV lipid-based delivery system for improved delivery of drugs with low partition coefficient. Journal of Liposome Research, 2015, 25, 325-333.	3.3	9

DINESH KUMAR

#	Article	IF	CITATIONS
19	Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 517-526.	1.6	8
20	The role of surface chemistry in crystal morphology and its associated properties. CrystEngComm, 2015, 17, 6646-6650.	2.6	7
21	Study of Different Crystal Habits of Aprepitant: Dissolution and Material Attributes. Applied Sciences (Switzerland), 2021, 11, 5604.	2.5	6
22	Can vacuum morphologies predict solubility and intrinsic dissolution rate? A case study with felodipine polymorph form IV. Journal of Computational Science, 2015, 10, 178-185.	2.9	5
23	Exploration of crystal simulation potential by fluconazole isomorphism and its application in improvement of pharmaceutical properties. Journal of Crystal Growth, 2014, 406, 18-25.	1.5	4
24	Modified crystal habits of glimepiride to improve manufacturing processability. Journal of Crystal Growth, 2022, 592, 126711.	1.5	2